Get the Stockscreener App
24.49
4.15%
-1.06
Oruka Therapeutics Inc stock is traded at $24.49, with a volume of 520.33K.
It is down -4.15% in the last 24 hours and up +55.29% over the past month.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
See More
Previous Close:
$25.55
Open:
$26
24h Volume:
520.33K
Relative Volume:
1.85
Market Cap:
$917.17M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+23.75%
1M Performance:
+55.29%
6M Performance:
+232.29%
1Y Performance:
-5.81%
1-Day Range:
$24.31
$26.04
1-Week Range:
$19.74
$26.04
52-Week Range:
$5.485
$31.13
Oruka Therapeutics Inc Stock (ORKA) Company Profile
Name
Oruka Therapeutics Inc
Sector
Industry
Phone
650-606-7910
Address
855 OAK GROVE AVE., MENLO PARK
Compare ORKA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
24.49 | 1.24B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-22-25 | Initiated | BTIG Research | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Outperform |
| Oct-11-24 | Initiated | Stifel | Buy |
| Oct-07-24 | Initiated | H.C. Wainwright | Buy |
| Sep-17-24 | Initiated | Leerink Partners | Outperform |
| Sep-16-24 | Initiated | TD Cowen | Buy |
| Sep-13-24 | Initiated | Jefferies | Buy |
| Feb-27-18 | Initiated | Ascendiant Capital Markets | Buy |
| Oct-09-13 | Initiated | Dawson James | Buy |
View All
Oruka Therapeutics Inc Stock (ORKA) Latest News
Is Oruka Therapeutics Inc. stock supported by strong cash flows2025 Investor Takeaways & Safe Entry Momentum Tips - newser.com
Automated trading signals detected on Oruka Therapeutics Inc.Options Play & Safe Capital Investment Plans - newser.com
Oruka Therapeutics (NASDAQ:ORKA) Trading Up 7.5%Should You Buy? - MarketBeat
Oruka Therapeutics (ORKA) Is Up 33.2% After Announcing $1.25B Shelf Registration and $200M Offering - Yahoo Finance
Weiss Ratings Reiterates Sell (D-) Rating for Oruka Therapeutics (NASDAQ:ORKA) - MarketBeat
How Oruka Therapeutics Inc. (HQ1) stock reacts to monetary easingBull Run & Weekly Top Gainers Trade List - newser.com
Why retail traders accumulate Oruka Therapeutics Inc. (HQ1) stockMarket Risk Summary & Daily Chart Pattern Signals - newser.com
How Oruka Therapeutics Inc. stock performs in stagflationLong Setup & Consistent Income Trade Ideas - newser.com
Can a trend reversal in Oruka Therapeutics Inc. lead to recoveryWeekly Stock Analysis & Community Consensus Picks - newser.com
What drives Oruka Therapeutics Inc stock priceMarket Entry Points & Budget Investment Success - earlytimes.in
Constellation Brands, Aehr Test Systems And 3 Stocks To Watch Heading Into Monday - Benzinga
How reliable is Oruka Therapeutics Inc. (HQ1) stock dividend growthSwing Trade & Advanced Technical Analysis Signals - newser.com
Should you wait for a breakout in Oruka Therapeutics Inc.Take Profit & Capital Efficiency Focused Ideas - newser.com
Oruka Therapeutics Inc Stock Analysis and ForecastValue Stock Picks & Free Real-Time Trading Alerts Every Day - earlytimes.in
Oruka Therapeutics files to sell 39.43M shares of common stock for holders - MSN
Oruka Therapeutics files for mixed shelf of upto $500 millionSEC filing - MarketScreener
Is Oruka Therapeutics Inc. forming a bottoming baseJuly 2025 Momentum & Risk Managed Investment Entry Signals - newser.com
Custom strategy builders for tracking Oruka Therapeutics Inc.2025 Analyst Calls & Daily Technical Forecast Reports - newser.com
What drives Oruka Therapeutics Inc HQ1 stock priceDividend Stability Analysis & Budget Friendly Growth - earlytimes.in
BTIG Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $56 - 富途牛牛
MoonLake Stock Climbs After-Hours: Retail Traders Shrug Off Record Plunge, More Wall Street Downgrades - Stocktwits
Oruka Therapeutics (NASDAQ:ORKA) Shares Gap UpWhat's Next? - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Receives Buy Rating from BTIG Research - MarketBeat
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Oruka Therapeutics Inc Stock (ORKA) Financials Data
There is no financial data for Oruka Therapeutics Inc (ORKA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Oruka Therapeutics Inc Stock (ORKA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Venrock Healthcare Capital Par | 10% Owner |
Feb 13 '25 |
Buy |
11.63 |
14,950 |
173,868 |
4,059,634 |
| Venrock Healthcare Capital Par | 10% Owner |
Feb 12 '25 |
Buy |
11.86 |
8,971 |
106,396 |
4,044,684 |
| Venrock Healthcare Capital Par | 10% Owner |
Feb 11 '25 |
Buy |
10.95 |
9,593 |
105,043 |
4,035,713 |
| Venrock Healthcare Capital Par | 10% Owner |
Feb 10 '25 |
Buy |
10.90 |
574 |
6,257 |
4,026,120 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):